. 2022 Dec 22;140(25):2754-2756.

doi: 10.1182/blood.2022016963.

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Andrew H Wei¹, Panayiotis Panayiotidis², Pau Montesinos³, Kamel Laribi⁴, Vladimir Ivanov⁵, Inho Kim⁶, Jan Novak⁷, Rebecca Champion⁸, Walter Fiedler⁹, Maria Pagoni¹⁰, Julie Bergeron¹¹, Stephen B Ting¹², Jing-Zhou Hou¹³, Achilles Anagnostopoulos¹⁴, Andrew McDonald¹⁵, Vidhya Murthy¹⁶, Takahiro Yamauchi¹⁷, Jianxiang Wang¹⁸, Qi Jiang¹⁹, Yan Sun¹⁹, Brenda Chyla¹⁹, Wellington Mendes¹⁹, Courtney D DiNardo²⁰

Affiliations

¹ The Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
² National and Kapodistrian University of Athens Medical School, Laiko General Hospital, Athens, Greece.
³ Hospital Universitario y Politécnico La Fe, Valencia, Spain and CIBERONC, Instituto Carlos III, Madrid, Spain.
⁴ Centre Hospitalier-Le Mans, Le Mans, France.
⁵ Almazov National Medical Research Center, Saint Petersburg, Russia.
⁶ Seoul National University Hospital, Seoul, Republic of Korea.
⁷ Department of Internal Medicine and Hematology, University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
⁸ Norton Cancer Institute, Louisville, KY.
⁹ Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹⁰ Evaggelismos General Hospital, Athens Greece.
¹¹ CIUSSS-EMTL, Installation Maisonneuve-Rosemont, Montreal, Quebec City, Canada.
¹² Eastern Health and Monash University, Melbourne, Victoria, Australia.
¹³ University of Pittsburgh Medical Center (UPMC) Cancer Center, Pittsburgh, PA.
¹⁴ George Papanicolaou General Hospital, Thessalonica, Greece.
¹⁵ Netcare Pretoria East Hospital, Moreletapark, Pretoria, South Africa.
¹⁶ Heartlands Hospital, Birmingham, United Kingdom.
¹⁷ University of Fukui Hospital, Fukui, Japan.
¹⁸ Chinese Academy of Medical Sciences, Tianjin, China.
¹⁹ AbbVie Inc., North Chicago, IL.
²⁰ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

PMID: 36112968
DOI: 10.1182/blood.2022016963

Free article

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Andrew H Wei et al. Blood. 2022.

Free article

. 2022 Dec 22;140(25):2754-2756.

doi: 10.1182/blood.2022016963.

Authors

Affiliations

¹ The Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
² National and Kapodistrian University of Athens Medical School, Laiko General Hospital, Athens, Greece.
³ Hospital Universitario y Politécnico La Fe, Valencia, Spain and CIBERONC, Instituto Carlos III, Madrid, Spain.
⁴ Centre Hospitalier-Le Mans, Le Mans, France.
⁵ Almazov National Medical Research Center, Saint Petersburg, Russia.
⁶ Seoul National University Hospital, Seoul, Republic of Korea.
⁷ Department of Internal Medicine and Hematology, University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
⁸ Norton Cancer Institute, Louisville, KY.
⁹ Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹⁰ Evaggelismos General Hospital, Athens Greece.
¹¹ CIUSSS-EMTL, Installation Maisonneuve-Rosemont, Montreal, Quebec City, Canada.
¹² Eastern Health and Monash University, Melbourne, Victoria, Australia.
¹³ University of Pittsburgh Medical Center (UPMC) Cancer Center, Pittsburgh, PA.
¹⁴ George Papanicolaou General Hospital, Thessalonica, Greece.
¹⁵ Netcare Pretoria East Hospital, Moreletapark, Pretoria, South Africa.
¹⁶ Heartlands Hospital, Birmingham, United Kingdom.
¹⁷ University of Fukui Hospital, Fukui, Japan.
¹⁸ Chinese Academy of Medical Sciences, Tianjin, China.
¹⁹ AbbVie Inc., North Chicago, IL.
²⁰ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

PMID: 36112968
DOI: 10.1182/blood.2022016963

Erratum in

Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022;140(25):2754-2756.
[No authors listed] [No authors listed] Blood. 2023 Nov 23;142(21):1846-1847. doi: 10.1182/blood.2023022753. Blood. 2023. PMID: 37995101 No abstract available.

No abstract available

PubMed Disclaimer

Cited by

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.
Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, Mehta P, Yassin H, Laurie J, Austin M, Gallipoli P, Taylor T, Dennis M, Elliot J, Clarke G, Dang R, Vidler J, Krishnamurthy P, Latif AL, Kalkur P, Shahidianakbar M, Campbell V, Mannari D, Sutherland E, Wickramaratne T, Collins A, Zhao R, Mak H, Belsham E, Banerjee S, Bashir J, Pillai S, Whitmill R, Galli S, Amer M, Murthy V, Murray D, Wandroo F, Hogan F, Crolla F, Fowler N, Khan A, O'Nions J, Dillon R. Othman J, et al. Blood Neoplasia. 2024 May 23;1(3):100017. doi: 10.1016/j.bneo.2024.100017. eCollection 2024 Sep. Blood Neoplasia. 2024. PMID: 40453057 Free PMC article. Clinical Trial.
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Sasaki K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Senapati J, et al. Cancer. 2024 Oct 1;130(19):3333-3343. doi: 10.1002/cncr.35388. Epub 2024 May 29. Cancer. 2024. PMID: 38809547 Clinical Trial.
Mitochondria and Acute Leukemia: A Clinician's Perspective.
Iyer P, Jasdanwala SS, Bhatia K, Bhatt S. Iyer P, et al. Int J Mol Sci. 2024 Sep 7;25(17):9704. doi: 10.3390/ijms25179704. Int J Mol Sci. 2024. PMID: 39273651 Free PMC article. Review.
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Bataller A, et al. Blood Adv. 2024 Feb 27;8(4):927-935. doi: 10.1182/bloodadvances.2023011757. Blood Adv. 2024. PMID: 38113472 Free PMC article.
Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
Im A, Quann K, Agha M, Raptis A, Redner RL, Hou JZ, Farah R, Dorritie KA, Sehgal AR, Normolle D, Bovbjerg DH, Aggarwal N, Herman J, Lontos K, Boyiadzis M. Im A, et al. Am J Hematol. 2024 Mar;99(3):380-386. doi: 10.1002/ajh.27212. Epub 2024 Jan 22. Am J Hematol. 2024. PMID: 38258329 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Affiliations

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Authors

Affiliations

Erratum in

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Erratum in

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical